<DOC>
	<DOCNO>NCT02422264</DOCNO>
	<brief_summary>The purpose study evaluate immunogenicity safety GSK Biologicals ' Infanrix hexa , give primary vaccination schedule infant bear pregnant woman participate study 116945 [ DTPA ( BOOSTRIX ) -047 ] . This study help u evaluate presence transplacentally transfer maternal antibody interfere immune response primary vaccination Infanrix hexa co-administered pneumococcal conjugate vaccine give part study infant .</brief_summary>
	<brief_title>Immunogenicity Safety Study Infanrix Hexa Healthy Infants Born Mothers Vaccinated With Boostrix™ During Pregnancy Immediately Post-delivery</brief_title>
	<detailed_description />
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Subjects ' parent ( ) /Legally Acceptable Representative ( ) [ LAR ( ) ] , opinion investigator , comply , requirement protocol ( e.g . completion diary card , return followup visit ) . Written inform consent obtain parent ( ) /LAR ( ) subject prior performing study specific procedure . A male female , 6 14 week age ( include 6 week include 14 week 6 day age ) time first vaccination . Healthy subject establish medical history clinical examination enter study . Born mother enrol study 116945 [ DTPA ( BOOSTRIX ) 047 ] . Medically stable* prematurely born infant , born gestation period 2736 week may enrol study discretion investigator . Medically stable refers condition premature infant require significant medical support ongoing management debilitate disease demonstrate clinical course sustain recovery time receive first dose study vaccine . Child care Chronic administration ( defined 14 day total ) immunosuppressant immunemodifying drug period start birth prior first vaccine dose . For corticosteroid , mean prednisone ≥0.5mg/kg/day , equivalent . Inhaled topical steroid allow . Administration longacting immunemodifying drug time study period ( e.g . infliximab ) . Administration chronic drug therapy continue study period . A vaccine foreseen study protocol administer period start 30 day dose vaccine end 30 day after* , exception inactivate influenza vaccine vaccine give part national/regional immunisation schedule , allow time study period . In case emergency mass vaccination unforeseen public health threat ( e.g . : pandemic ) organise public health authority , outside routine immunisation program , time period describe reduced necessary vaccine provide license use accord SPC package insert ( PI ) accord local governmental recommendation provide write approval Sponsor obtain . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational vaccine/product ( pharmaceutical product device ) . Previous vaccination Hib , diphtheria , tetanus , pertussis , pneumococcus , and/or poliovirus since birth . History Hib , diphtheria , tetanus , pertussis , pneumococcal , poliovirus hepatitis B disease . Any confirm suspected immunosuppressive immunodeficient condition include severe combine immunodeficiency disease ( SCID ) , base medical history physical examination ( laboratory testing require ) . Family history congenital hereditary immunodeficiency . History reaction hypersensitivity likely exacerbate component vaccine . Major congenital defect Serious chronic illness . History neurological disorder seizure . Acute disease and/or fever time enrolment . Fever define temperature ≥37.5°C/99.5°F oral , axillary tympanic route , ≥38.0°C/100.4°F rectal route . Subjects minor illness ( mild diarrhoea , mild upper respiratory infection ) without fever may , enrol discretion investigator . Administration immunoglobulins and/or blood product period start birth first dose study vaccine plan administration study period . Hypersensitivity latex .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>14 Weeks</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>